Rodney R Miles
Overview
Explore the profile of Rodney R Miles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
904
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li P, Alnoor F, Xie W, Williams M, Feusier J, Ding Y, et al.
Leukemia
. 2024 Nov;
39(1):248-256.
PMID: 39516371
No abstract available.
2.
Guest E, Kairalla J, Devidas M, Hibbitts E, Carroll A, Heerema N, et al.
Haematologica
. 2024 Jun;
109(12):3918-3927.
PMID: 38867582
Infants less than 1 year old diagnosed with KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL) are at high risk of failure to achieve remission, relapse, and death due to leukemia, despite...
3.
Hayashi R, Hermiston M, Wood B, Teachey D, Devidas M, Chen Z, et al.
Blood
. 2024 Mar;
143(20):2053-2058.
PMID: 38457359
Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children's Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or...
4.
Grant G, Sahni D, Florell A, Hull C, Florell S, Miles R, et al.
JAAD Case Rep
. 2023 Apr;
34:86-89.
PMID: 37025561
No abstract available.
5.
Burke G, Minard-Colin V, Auperin A, Alexander S, Pillon M, Delgado R, et al.
J Clin Oncol
. 2022 Apr;
40(18):2064-2066.
PMID: 35377710
No abstract available.
6.
Teachey D, Devidas M, Wood B, Chen Z, Hayashi R, Hermiston M, et al.
J Clin Oncol
. 2022 Mar;
40(19):2106-2118.
PMID: 35271306
Purpose: To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III...
7.
Underdown M, Miles R, Gross T, Winters A
Pediatr Blood Cancer
. 2021 Dec;
69(3):e29527.
PMID: 34962700
No abstract available.
8.
Li P, Venkatachalam S, Ospina Cordona D, Wilson L, Kovacsovics T, Moser K, et al.
Blood Adv
. 2021 Oct;
6(2):405-409.
PMID: 34649277
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by somatic mutations in UBA1 and is identified by a genotype-driven method. This condition affects unrelated men with adultonset inflammatory...
9.
Burke G, Minard-Colin V, Auperin A, Alexander S, Pillon M, Delgado R, et al.
J Clin Oncol
. 2021 Sep;
39(33):3716-3724.
PMID: 34570655
Purpose: A dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) regimen has been shown to deliver excellent survival for adults with primary mediastinal large B-cell lymphoma...
10.
Mangum D, Meyer J, Mason C, Shams S, Maese L, Gardiner J, et al.
JAMA Oncol
. 2021 Aug;
7(10):1521-1528.
PMID: 34410295
Importance: Alterations in the IKZF1 gene drive B-cell acute lymphoblastic leukemia (B-ALL) but are not routinely used to stratify patients by risk because of inconsistent associations with outcomes. We describe...